All In Biotech

Drug Trial Radar · NCT05300035

Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control

A Randomised Phase II Placebo-controlled Trial of Antiretroviral Therapy (ART) Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs) vs ART Plus Placebo During Primary HIV-1 Infection to Study the Impact on Post-treatment HIV Control.

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

69

Planned (sponsor's estimate)

Start

Apr 11, 2024

Primary completion

Dec 10, 2026

Study completion Dec 10, 2028

Sponsor

Lead sponsor
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Rockefeller University; Institut Pasteur
First posted
Mar 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RHIVIERA-02 trial is a placebo-controlled double-blinded two arm prospective phase II trial. This study will test the use of broadly neutralising antibodies (bNAbs) in participants, at primary HIV infection (PHI) and ART initiation.

Conditions

  • HIV/AIDS and Infections

Interventions

  • Recombinant human monoclonal antibody (bNAbs)Drug

    1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of bNAbs (3BNC117LS \& 10-1074LS) between Day 7 and Day 10. 2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions. 3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks. 4. ART resumption, if participant encounters at least one ART resumption criteria.

  • PlaceboDrug

    1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of placebo (saline solution) between Day 7 and Day 10. 2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions. 3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks. 4. ART resumption, if participant encounters at least one ART resumption criteria.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with plasma HIV-1 RNA below 400 cp/mL 24 weeks following ATI (W24 ATI), in the confirmed absence of ART.Time frame: at Week 24 of antiretroviral treatment interruption period (ATI)

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Hôpial Avicenne - SMIT

    Bobigny, France · Recruiting

  • Hôpital Antoine Béclère

    Clamart, France · Recruiting

  • Hôpital Beaujon - Service de médecine interne

    Clichy, France · Recruiting

  • CHI Créteil - HdJ

    Créteil, France · Recruiting

  • Hôpital Raymond Poincaré - SMIT

    Garches, France · Recruiting

  • Hôpital Bicêtre - HdJ - Médecine interne

    Le Kremlin-Bicêtre, France · Recruiting

  • Hôpital Hôtel - Dieu

    Paris, France · Recruiting

  • Hôpital Hôtel Dieu - Service d'immunologie clinique

    Paris, France · Not yet recruiting

  • Hôpital Pitié-Salpêtrière - SMIT

    Paris, France · Recruiting

  • Hôpital Lariboisière - Service de médecine interne A

    Paris, France · Recruiting

  • Hôpital Saint- Louis - SMIT

    Paris, France · Recruiting

  • Hôpital Saint-Antoine - SMIT

    Paris, France · Recruiting

  • Hôpital Necker - SMIT

    Paris, France · Recruiting

  • Hôpital Bichat - Claude Bernard - SMIT

    Paris, France · Recruiting

  • Hôpital Tenon - SMIT

    Paris, France · Recruiting

  • Centre médico chirurgical Foch - Suresnes

    Suresnes, France · Recruiting

  • CHI Villeneuve-Saint-Georges - SMIT

    Villeneuve-Saint-Georges, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.